| # | % | |||||
|---|---|---|---|---|---|---|
| 1 | ABBVIE INC | 11,232,758 | 703,395,000 | 33.86% | ||
| 2 | PROTHENA CORP PLC | 10,310,511 | 507,174,000 | 24.42% | ||
| 3 | ALKERMES PLC SHS | 7,451,128 | 414,134,000 | 19.94% | ||
| 4 | Theravance Biopharma Inc | 10,507,608 | 334,983,000 | 16.13% | ||
| 5 | BIOGEN INC | 248,530 | 64,918,000 | 3.13% | ||
| 6 | GILEAD SCIENCES INC | 614,300 | 43,990,000 | 2.12% | ||
| 7 | NORTHWEST BIOTHERAPEUTICS INC | 24,815,028 | 8,638,000 | 0.42% |
Portfolio data is normalized using SEC Form 13F filings, including the Restatement filing (0001213900-17-005688, filed 2017.05.22).
From 2023-01-03 onward, the SEC requires values to be reported in nearest dollars. Earlier filings reported values in thousands; therefore, positions shown as $0 in older filings may represent actual values between $0–$999.
